ABCA2 and chronic myelogenous leukemia, BCR-ABL1 positive: Some of the studies showed that the level of ABCA2 protein in patients having chronic myeloid leukemia has no relationship with response to imatinib drug (51),while, some otherstudieshave shown that ABCA2 protein leads to drug resistancein T-ALL and AML (83).